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Abstract  52 
Objective:  53 
ATL1103 is a second-generation antisense oligomer targeting the human GH receptor. This phase 2 54 
randomised, open-label, parallel-group study assessed the potential of ATL1103 as a treatment for 55 
acromegaly. 56 
Design:  57 
26 patients with active acromegaly (IGF-I >130% upper limit of normal) were randomised to 58 
subcutaneous ATL1103 200 mg either once- or twice-weekly for 13 weeks, and monitored for a further 59 
8-week washout period.  60 
Methods:  61 
The primary efficacy measures were change in IGF-I at week 14, compared to baseline and between 62 
cohorts.  For secondary endpoints (IGFBP3, ALS, GH, GHBP), comparison was between baseline 63 
and week 14. Safety was assessed by reported adverse events. 64 
Results and Conclusions:  65 
Baseline median IGF-I was 447 and 649 ng/mL in the once- and twice-weekly groups, respectivey. 66 
Compared to baseline, at week 14 twice-weekly ATL1103 resulted in a median fall in IGF-I of 27.8% 67 
(p=0.0002). Between cohort comparison at week 14 demonstrated the median fall in IGF-I to be 25.8% 68 
(p=0.0012) greater with twice-weekly dosing. In the twice-weekly cohort, IGF-I was still declining at 69 
week 14, and at week 21 remained lower than at baseline by a median of 18.7% (p=0.0005).  70 
 71 
Compared to baseline, by week 14 IGFBP3 and ALS had declined by a median of 8.9% (p=0.027) and 72 
16.7% (p=0.017) with twice-weekly ATL1103;  GH had increased by a median of 46% at week 14 73 
(p=0.001).  IGFBP3, ALS and GH did not change with weekly ATL1103. GHBP fell by a median of 74 
23.6% and 48.8% in the once- and twice-weekly cohorts (p=0.027 and p=0.005), respectively. 75 
ATL1103 was well tolerated, although 84.6% of patients experienced mild to moderate injection-site 76 
reactions (ISR).  77 
This study provides proof-of-concept that ATL1103 is able to significantly lower IGF-I in patients with 78 
acromegaly.   79
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Introduction  82 
Acromegaly is a rare, chronic, life-shortening disease caused by hypersecretion of growth hormone 83 
(GH), virtually always due to a pituitary adenoma, that in turn results in elevated circulating levels of 84 
insulin-like growth factor 1 (IGF-I).1 Conventional therapy is directed at the pituitary gland and attempts 85 
to reduce GH secretion by means of surgery, radiotherapy, or medical therapy in the form of 86 
somatostatin analogues and dopamine agonists.2 The GH receptor antagonist pegvisomant has 87 
successfully exploited an alternative therapeutic approach, namely to block GH action rather than 88 
secretion.3 89 
Antisense oligonucleotides (ASOs) are single-stranded synthetic oligonucleotides that have been 90 
developed as therapeutic agents.  Translation of messenger RNA (mRNA), and hence protein synthesis, 91 
is inhibited by sequence-specific ASOs which bind target pre-mRNA and/or mRNA.4  In the early 92 
1990s, clinical trials with ASOs began, and in 1998 fomivirsen became the first oligonucleotide to be 93 
approved by the U.S Food and Drug Administration (FDA) for the treatment of cytomegalovirus 94 
retinitis.5 In 2013, the second-generation ASO inhibitor mipomersen was approved by the FDA for the 95 
treatment of homozygous familial hypercholesterolaemia. Currently, there are more than 30 second-96 
generation ASOs, including ATL1103, in clinical development for a variety of neurological, 97 
oncological, cardiovascular, and metabolic conditions. Excellent reviews of the technology are 98 
available elsewhere.6  99 
 100 
ATL1103 is a second-generation, antisense oligomer designed to inhibit translation of human growth 101 
hormoe receptor (GHR) mRNA (Figure 1). It comprises 20 nucleotides with a phosphorothioate 102 
backbone and 2’-O-methoxyethyl modifications of the terminal five nucleotides at each end, which in 103 
combination increase its plasma half-life and affinity for the mRNA. Post-hybridization RNaseH 104 
degradation results in inhibition of GHR translation. In pre-clinical rodent and primate studies, 105 
ATL1103 reduced GHR mRNA levels in the liver and serum IGF-I, with a terminal half-life of 2 to 4 106 
weeks (add Tachas JoE 2006 189 147) Phase 1 studies in healthy male volunteers demonstrated a fall 107 
in serum IGF-I and growth hormone binding protein (GHBP) 108 
(https://www.asx.com.au/asxpdf/20111207/pdf/4234016x2cj5xn.pdf). 109 
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 110 
The objectives of this study were to evaluate the safety, tolerability, and efficacy of ATL1103 in patients 111 
with acromegaly. Serum IGF-I was the primary measure of efficacy, with the other components of the 112 
IGF ternary complex, namely IGF-binding protein 3 (IGFBP3) and acid labile subunit (ALS) being 113 
additional measures of disease activity. Circulating GH and GHBP, the cleaved extracellular component 114 
of the GHR, were monitored to provide insight into the physiological implications of an ASO targeting 115 
the GHR.  For the primary efficacy variable, the null hypothesis of no percentage change in fasting 116 
IGF-I levels from baseline to week 14 was tested for each treatment regimen.  117 
 118 
Subjects and Methods 119 
 120 
Study Design 121 
 122 
This was a phase 2 randomised, open-label, parallel-group study of the safety, tolerability, 123 
pharmacokinetics, and efficacy of two subcutaneous dosing regimens of ATL1103 in patients with 124 
acromegaly (Figure 2). 125 
 126 
Exclusion/Inclusion Criteria 127 
 128 
Inclusion criteria 129 
Patients who:  130 
1. provided written informed consent in accordance with local regulations   131 
2. were 18 to 80 years of age inclusive 132 
3. had acromegaly due to pituitary adenoma (micro- or macroadenoma) identified by magnetic 133 
resonance imaging (MRI) 134 
4.  had serum IGF-I level at screening >1.3 times the upper limit of normal (ULN) 135 
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5. had documented serum GH nadir levels >1 ng/mL at all test time points within the 2 hours post 136 
oral glucose load for an oral glucose tolerance test (OGTT) (this could be historical) 137 
6. were acromegaly treatment naïve, or who had not taken other acromegaly medications for at 138 
least the following periods of time prior to IGF-I and GH screening tests: bromocriptine: 6 139 
weeks;  carbergoline: 8 weeks;  quinagolide: 8 weeks;  octreotide (subcutaneous): 4 weeks; 140 
pegvisomant: 8 weeks;  octreotide LAR: 4 months;  lanreotide (all presentations): 4 month 141 
7. had a body mass index (BMI) ≥19 kg/m2 142 
8. had adequate venous access to allow collection of multiple blood samples during the study 143 
9. were female of non-child-bearing potential (i.e., either surgically sterilised or at least 1 year 144 
post-menopausal), or, if of child-bearing potential, agreed to use two approved methods of 145 
contraception for the duration of the study and for 3 months after administration of the last dose 146 
of study drug; or were male and surgically sterilised or agreed to use an approved method of 147 
contraception for the duration of the study and until 3 months after administration of the last 148 
dose of the study medication 149 
10. were willing and able to self-administer subcutaneous injections  150 
 151 
(Inclusion criteria 5, 6, and 9 were amended in protocol amendments during the study. For inclusion 152 
criterion 5, the requirement for GH after OGTT at screening was altered, as this could be historical. 153 
Inclusion criterion 6 was amended to clarify that the washout periods detailed were minimum periods. 154 
For inclusion criterion 9, contraceptive requirements were clarified.)  155 
 156 
Exclusion criteria  157 
Patients who:  158 
1. had acromegaly due to reasons other than pituitary adenoma 159 
2. had a pituitary adenoma that was less than 3 mm distance from the optic chiasm 160 
3. had undergone pituitary surgery within the 3 months preceding the Screening visit 161 
4. had received pituitary radiotherapy within the 1 year preceding the Baseline visit 162 
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5. had insulin-treated diabetes, or had commenced a new hypoglycaemic drug for diabetes within 163 
the 2 months prior to Screening 164 
6. had congestive heart failure, unstable angina, clinically significant cardiac arrhythmia, or a 165 
history of acute myocardial infarction within the 3 months preceding the Baseline visit 166 
7. had abnormal hepatic function at Screening defined any of the following parameters >2 x ULN: 167 
aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl 168 
transferase (GGT), alkaline phosphatase (ALP), prothrombin time or total bilirubin 169 
8. had hepatitis B, hepatitis C, or chronic liver disease 170 
9. were pregnant or lactating 171 
10. had known human immunodeficiency virus [(HIV) not tested specifically for this protocol], or 172 
history of immunodeficiency that may have compromised their safety or affect results from this 173 
study  174 
11. had a history of alcohol or drug abuse in the 6 month period preceding the Baseline visit 175 
 176 
Patients were recruited in 13 tertiary referral centres in Australia, France, Spain, and the United 177 
Kingdom.  178 
 179 
Appropriate ethical approval was obtained in every jurisdiction, and the study was registered as 180 
EudraCT 201200314730 and ANZCTR 12611000854932.  Patients gave written informed consent.    181 
 182 
Procedures and Study Medication 183 
Patients received either ATL1103 200 mg once or twice weekly 3 and 4 days apart for 13 weeks, with 184 
every patient receiving three doses in the first week, administered every other day.  Based on the tissue 185 
half-life of >4 weeks, experience from primate studies and data from the phase 1 study, additional 186 
‘loading’ doses were administered in the first week.   187 
 188 
ATL1103 is formulated as a ‘ready-to-inject’ sterile solution at a concentration of 200 mg/mL, pH 7·4, 189 
in ‘Water for Injection’.  Patients were taught to self-administer ATL1103 subcutaneously. After 190 
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completion of drug administration at the end of 13 weeks, patients were monitored, off all therapy for 191 
acromegaly, for a further 8 weeks. 192 
All patients underwent pituitary MRI scans at baseline and at week 13 (completion of the study drug), 193 
which were independently reviewed by two ‘blinded’ expert pituitary neurosurgeons.  Tumour diameter 194 
changes of 2 mm or more in any one dimension or tumour volume changes of more than 20% were 195 
considered significant.  196 
 197 
An OGTT with measurement of plasma glucose and serum GH was undertaken at baseline (after any 198 
drug washout) and again at the end of week 13. An adverse event (AE) assessment was undertaken at 199 
each of the 11 study visits from baseline until study conclusion.  200 
 201 
In addition to routine safety parameters, serum IGF-I, insulin-like growth factor binding protein 3 202 
(IGFBP3), ALS, and GHBP were monitored. Ring size (fourth digit left hand) was measured using 203 
standard European-sized jewelers’ ring sets, and patients completed a signs and symptoms score (SSS, 204 
maximum score 40) and the disease-generated ‘quality of life’ AcroQol. AcroQol comprises 22 205 
questions divided into two main categories: physical and psychological function. The psychological 206 
category is further subdivided into appearance and personal relationships. Each question is scored out 207 
of 5, with a maximum score of 110 reflecting best possible quality-of-life. The result is then converted 208 
to a percentage.7   209 
 210 
Randomisation and Blinding 211 
Permuted block randomisation (generated by a statistician and imported into the electronic case report 212 
form) was used to assign patients to either open-label, once- or twice-weekly ATL1003.  Once initial 213 
data for a patient had been entered and the patient had fulfilled all inclusion criteria, a randomisation 214 
number and treatment regimen were generated. Treatment allocation was not known to the operational 215 
personnel until this randomisation was performed.  216 
Blocks of size 4 were used with no stratification for the first 24 patients. The list included an 217 
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additional 24 randomisation numbers using a block size of 2 (total 48) to allow for overage.  218 
 219 
Assays 220 
IGF-I, GH, and IGFBP3 221 
Serum IGF-I, GH, and IGFBP3 were measured centrally by IDS-iSYS (Immunodiagnostic Systems, 222 
[IDS] Ltd., Boldon, England, UK) assays at the Endocrine Laboratory, Universität München (Munich, 223 
Germany). Recombinant standards (98/574 for GH and 02/254 for IGF-I) yielded inter-assay 224 
variability of 4.0–8.7% (IGF-I) and 1.1–3.4% (GH) and sensitivity of 8.8 ng/mL (IGF-I) and 0.04 225 
ng/mL (GH).8, 9 The limit of quantification for IGFBP3 was 50 ng/mL and the intra- and interassay 226 
coefficients of variation (CVs) were 4·2% and 6·9%, respectively.10  227 
 228 
ALS 229 
Serum ALS levels were measured in duplicate by sandwich immunometric assay using monoclonal 230 
antibodies directed against specific N- and C-terminal oligopeptides.11 A serum pool of healthy male 231 
volunteers was used for calibration and assigned 1000 U/litre. The assay range is 500 to 5000 U/litre, 232 
and the intra- and interassay CVs were less than 9%. All samples from an individual subject were 233 
analysed in one run.  234 
 235 
GHBP 236 
Serum GHBP levels were measured by a modification of the ligand immunofunctional assay with an 237 
in-house monoclonal anti-GHBP antibody. Within-assay CVs were 9.4% at 115 pmol/L and 6.1% at 238 
1550 pmol/L. At the same concentrations, between-assay CVs were 8.5% and 10.9%, respectively. 239 
The lower limit of quantification was 69 pmol/L, and the linear range was 69–3500 pmol/L. All 240 
samples from an individual subject were analysed in one run.12  241 
 242 
Statistics 243 
The study was powered for within-group comparison of serum IGF-I (primary efficacy variable).  244 
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Based on a published pegvisomant study,3 a clinically meaningful reduction in baseline IGF-I was 245 
determined to be 27.5%, with a conservative estimate of standard deviation of 30%. To achieve a 246 
level of significance of 0.05 with a two-sided test, it was determined that a minimum sample size of 247 
12 patients per treatment was required to achieve a power of at least 80%.  248 
 249 
The planned efficacy analyses were within the intention-to-treat group.  For the primary efficacy 250 
variable, the null hypothesis of no percentage change in fasting IGF-I levels from baseline to week 14 251 
was tested for each treatment group with a (two-sided) one-sample t test and Wilcoxon signed rank 252 
test. In addition, a pre-specified, though not powered for between-treatment-groups, comparison was 253 
performed using a Wilcoxon Rank Sum test (mathematically equivalent to Mann-Whitney U test) for 254 
serum IGF-I one week after the last dose of study drug (week 14).  255 
 256 
Baseline to week 14 testing for both cohorts was undertaken (Wilcoxon signed rank test) for each of 257 
the secondary endpoints (the other components of the IGF ternary complex, namely IGFBP3 and 258 
ALS, plus circulating GH and GHBP, SSS, ring size, and AcroQoL) and presented as median plus 259 
range.   260 
 261 
A post-hoc regression analysis of the relationship between change in IGF-I and dose/kg/week is 262 
reported with the associated 95% CI. Comparison of trapezoidal area-under-the-curve for GH during 263 
the OGTTs is reported. Statistical significance is indicated by a p value <0.05.   264 
 265 
Serum IGF-I data are expressed in mass units (ng/mL) and as a percentage of the upper limit of the 266 
age-related reference range.  267 
 268 
Data Safety Monitoring Board 269 
An independent Data Safety Monitoring Board (DSMB) was established prior to recruitment start, 270 
with an appropriate charter to direct decisions and monitor the trial safety results at intervals 271 
throughout the study, and provided their recommendations as to whether the trial could continue as 272 
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planned or whether there were any concerns. The DSMB comprised four individuals with appropriate 273 
experience in the areas of acromegaly, endocrine disorders, statistics, and the conduct of clinical 274 
trials. 275 
 276 
Results  277 
 278 
Participants  279 
Thirteen patients with active acromegaly (IGF-I >130% ULN at screening visit) (detailed in Table 1 280 
and Figure 3) were recruited into each study arm. 281 
 282 
Efficacy 283 
IGF-I (Figures 4 and 5) 284 
 285 
At baseline, the median serum IGF-I was 447 ng/ml (205–975)(2.5 x ULN) and 649 ng/ml (239–286 
831)(2.75 x ULN) ng/mL, in the once- and twice-weekly groups, respectively. Compared to baseline, 287 
at week 14, ATL1103 at a dose of 200 mg twice weekly resulted in a median fall in serum IGF-I of 288 
27.8% (range 4.4 to 49.8%, p=0.0002), while no change was seen with once-weekly dosing. At week 289 
14, the median fall in IGF-I was 25.8% greater with twice-weekly compared to once-weekly dosing 290 
(p=0.0012). In the twice-weekly cohort, IGF-I levels were still declining at week 14, and at the end of 291 
the washout (week 21) remained lower than at baseline by a median of 18.7% (p=0.0005). 292 
 293 
In both dosing regimens, one patient had an IGF-I within the age-related reference range at the pre-294 
defined endpoint of week 14.  Normalisation of IGF-I at any time point was a pre-defined outcome 295 
measure and was met by one additional patient in the twice-weekly regimen (week 13).   296 
 297 
Combining the data from the two dosing regimens, regression analysis of the percentage change in 298 
IGF-I levels versus dose/kg/week (median 2.88 (range 1.52 – 6.90) demonstrated an estimated slope 299 
of regression of –8.27, indicative of a highly statistically significant (p=0.0001) association between 300 
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fall in IGF-I and the dose/kg/week (Figure 6).   301 
 302 
IGFBP3 303 
In the twice-weekly cohort, at week 14, there was a median fall in serum IGFBP3 of 8.9% (range -304 
29.2 to 12.9%, p=0.027) from baseline (median 7005 ng/ml, range 3396-9843). Once-weekly 305 
ATL1103 did not result in a significant change in serum IGBP3.  306 
 307 
ALS 308 
Compared to baseline, twice-weekly ATL1103 resulted in a median fall in ALS at week 14 of 16.7% 309 
(range -20.9 to 34.9%, p=0.017)  from baseline (median 1970 mU/ml, range 945-2463). Once-weekly 310 
ATL1103 did not result in a significant change in serum ALS.  311 
 312 
GH (Figure 7)  313 
In the twice-weekly cohort, median trapezoidal AUC for GH during the OGTT had increased by 46%  314 
(range -5.4 to 419%, p=0.001) at week 14 compared to baseline (471 ng.min/ml (79-867)).  There was 315 
no change in GH levels in the once-weekly cohort.    316 
 317 
GHBP (Figure 8) 318 
There was a significant decline in serum GHBP levels in both cohorts at week 14. Twice-weekly 319 
ATL1103 resulted in a median decline of 48.8% (range -9.8 to 94.1%, p=0.005) in GHBP from 320 
baseline (525 pmol/l (<69-6434), while a median fall of 23.6% (range -61.4 to 59.4%, p=0.027) was 321 
seen in the once-weekly cohort (1179 pmol/l (386-7637), p=0.027) and was maintained through to 322 
week 21. In the twice-weekly cohort, the median fall in serum GHBP at week 21 was 40.4% (range -323 
94.1 to 6.1%, p=0.008) compared to baseline.  324 
 325 
Ring Size 326 
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There was a statistically significant decrease in ring size circumference (mm) from baseline to week 327 
13 for regimen 2, with a median decrease of –1·25 mm (range -12.6  to 3.8, p=0.039).  Ring size was 328 
unchanged with once-weekly dosing. 329 
 330 
Signs and Symptoms Score 331 
There was no marked difference in either regimen in median SSS at baseline (20 [1–36] vs 11 [7-30]). 332 
The median percentage fall  from baseline at week 14 was greater for twice-weekly dosing  37.5% 333 
(range -185.7% to 91.7%) compared with 10.2% (range -33.3 to 83.3%) for once-weekly dosing, 334 
although the changes were not statistically significant. 335 
 336 
AcroQol 337 
The median absolute improvement in the physical dimension and global scores between baseline and 338 
week 14 in the once-weekly were 6.25 (range 0 to 31.3, p=0.002) and 3.4 (range -2.3 to 14.8, 339 
p=0.0068) respectively, but these parameters did not change significantly with twice-weekly 340 
ATL1103.  341 
In contrast, in the twice weekly cohort, comparing baseline to week 14, the only significant finding  342 
was an improvement in the median absolute change for the appearance subsection of psychological 343 
dimension of 10.7 (range -17.9 to 25.0, p=0.035). There was no significant improvement in the once-344 
weekly cohort. 345 
 346 
Safety (Table 2) 347 
ATL1103 was well tolerated with mild to moderate injection site reactions (ISR) being the most 348 
common, affecting 85% of patients in both cohorts, drug-related AE. Four serious AEs (SAEs) were 349 
reported, of which three occurred in a single patient taking the once-daily regimen (acute bronchitis, 350 
loss of consciousness while driving, and cholecystitis) and one in a patient taking the twice-daily 351 
regimen (ear infection), but none were felt to be study drug–related, and both patients completed the 352 
13 weeks of therapy.  Two patients from one centre ‘withdrew consent’ at completion of dosing 353 
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(weeks 13 and 14) with study drug and so did not participate in the washout period through to week 354 
21.  355 
 356 
One patient in each regimen had low circulating platelet levels at a single time point (weeks 4 and 13, 357 
86 and 132 x 109/L, respectively; normal range 150 x 109/L), but these resolved either spontaneously 358 
or after treatment end (week 13). Two patients had elevated liver enzymes judged clinically 359 
significant: one patient taking the once-daily regimen had γ-glutamyltransferase, AST, ALT, and ALP 360 
values above the normal limit (>ULN); one patient taking the twice-daily regimen had AST and ALT 361 
values >ULN. All effects on liver function were transient (Table 3).   362 
 363 
The treatment-emergent AE (TEAE) profile was comparable for the two treatment groups 364 
(Supplemental Table 2). Almost all patients experienced ISRs (mild and moderate), and ‘mild’ 365 
lipohypertrophy, that subsequently, resolved was reported in two patients.  There was a greater 366 
incidence of headache in the once-weekly versus twice-weekly regimen (21 events and 5 events, 367 
respectively), but the number of patients who experienced headache was comparable: 4 patients in the 368 
once-daily regimen compared with 3 patients in the twice-daily regimen. 369 
 370 
Radiologically significant tumour diameter changes (2 mm or more in any one dimension or tumour 371 
volume changes of more than 20%) were reported in three patients. Tumour volume increased in two 372 
patients (one in each dosing regimen, 5.7 x 7.3 x 19.1 v 6.8 x 9.9 x 19.5 mm and 8.1 x 5.8 x 14.8 v 8.1 373 
x 7.2 x 16.2 mm) and reduced in one patient on twice-weekly dosing (6.2 x 10.4 x 4.9 v 2.6 x 5.7 x 4.1 374 
mm). The changes were judged not to be clinically significant.  375 
 376 
Discussion 377 
The technology underpinning ASO therapy is rapidly advancing and has the potential to offer new 378 
therapeutic options across a broad spectrum of diseases.  Disordered protein production or function is 379 
implicated in most pathological processes, and ‘gene silencing or activating’ by single-stranded 380 
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antisense oligonucleotides against target RNA sequences is an attractive concept that permits greater 381 
specificity than can be achieved with small molecules or antibodies.13  The synthetic structural 382 
modifications, such as the phosphorothioate backbone and 2’-O- methoxyethyl modifications, can be 383 
readily applied to whole classes of ASOs with only the nucleotide sequence being indication specific.  384 
Encouraging studies of ASOs are being reported against many targets, but this is the first report of the 385 
use of an ASO in endocrinology.  386 
The data presented provide the ‘proof-of-concept’ that in patients with acromegaly an ASO targeting 387 
the GHR can lower serum IGF-I and raise the prospect of a new and entirely novel therapy for 388 
acromegaly. Thirteen weeks of ATL1103 at a dose of 200 mg twice weekly lowered median serum 389 
IGF-I by 27.8%, with two (15%) of 13 patients achieving an IGF-I within the reference range. Serum 390 
IGF-I levels were still declining at week 14 and had not returned to baseline by the end of the 8-week 391 
(week 21) washout period (Figure 4), suggesting that the duration of ATL1103 therapy was too short 392 
to see maximum benefit and that prolonged treatment at the same doses may result in a further decline 393 
in serum IGF-I. First-order drug kinetics indicate that approximately four to five elimination half-lives 394 
are required to achieve steady-state plasma concentrations; since the tissue half-life of ATL1103 is 395 
believed to be >4 weeks,14 this would suggest that between 16 to 20 weeks of treatment would be 396 
required for nadir IGF-I levels to be achieved.  397 
 398 
In conjunction with the data indicating a relationship between the dose per kilogram per week and the 399 
fall in serum IGF-I, it seems probable that larger doses of ATL1103 administered for longer are likely 400 
to result in a greater fall in IGF-I and offer the prospect of ‘normalisation’ of IGF-I in a greater 401 
proportion of patients.  Reassuringly, the decline in serum IGF-I with twice-weekly treatment was 402 
paralleled by falls in the other elements of the IGF ternary complex, namely IGFBP3 and ALS. 403 
  404 
Circulating GHBP is the product of cleavage of the extracellular component of the GH receptor.15 In 405 
acromegaly there is a negative correlation between serum GHBP concentrations and IGF-I and GH 406 
levels (Kratzsch Eur J Endocrinol 1995;132(3): 306e12), such that in active acromegaly GHBP 407 
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concentrations are decreased, and increase with conventional therapy.   In contrast, the the reduction 408 
in IGF-I caused by ATL1103 therapy is associated with a significant decline in serum GHBP 409 
concentrations, which were still falling at week 14 and had not returned to baseline by the end of 410 
washout at week 21. The fall in GHBP likely reflects the ATL1103-induced down-regulation of GHR 411 
cell surface number, with a dose-response observed, as the fall was greater with the twice-weekly 412 
compared to once-weekly regimen, 23.6% and 48.8%, respectively. The changes in GHBP emphasise 413 
the difference in action of ATL1103 and future studies with increased doses of ATL1103 and larger 414 
cohorts will permit exploration of the relationship between the change in serum IGF-I and circulating 415 
GHBP concentrations.   416 
 417 
As with pegvisomant, the reduction in serum IGF-I with twice-weekly ATL1103 was associated with 418 
a 46% increase in serum GH levels assessed during an OGTT. Studies with pegvisomant have 419 
demonstrated that the increased GH secretion is a consequence of negative feedback in response to the 420 
fall in circulating IGF-I induced by blocking GH action. 17  421 
It is encouraging that an improvement in the soft-tissue manifestations of acromegaly, indicated by 422 
the reduction in ring size, was seen with twice-weekly therapy.  The short duration of therapy and 423 
small cohort size means it should not be a surprise that the fall in IGF-I was not associated with an 424 
improvement in SSS and only very modest improvements in quality of life as measured by AcroQol. 425 
Studies in larger numbers of patients treated for longer are required to demonstrate the impact of 426 
ATL1103 on well-being and quality of life.  427 
 428 
Almost all patients, approximately 85%, experienced ISRs, but otherwise ATL1103 was generally 429 
well tolerated with no apparent drug-related SAEs. There were four SAEs, of which three occurred in 430 
one patient, and all were judged to be unlikely to be drug related; both patients completed the 13 431 
weeks of therapy (Table 2). ISRs are a recognised side effect of second-generation ASOs; were mild 432 
to moderate in severity (predominantly a mixture of erythema, pain, and pruritus); and affected both 433 
cohorts equally.  No patient withdrew from this study because of ISRs.  This is a similar incidence of 434 
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ISRs as reported in other studies: 90% of patients participating in a phase 2 study of mipomersen 435 
experienced mild to moderate ISRs.18 The mechanism of oligonucleotide-induced ISR is yet to be 436 
fully elucidated, but skin biopsies in 9 of 32 subjects participating in a phase 1 study of mipomersen 437 
were consistent with leukocytoclastic vasculitis (e.g., infiltrating neutrophils, prominent nuclear dust, 438 
lymphocytes, and eosinophils with local macrophage infiltration).19 The lessons learned from the 439 
numerous other ASOs under clinical development will inform the management of ISRs in future 440 
studies of ATL1103. Transient changes in platelet count and liver function were encountered but were 441 
judged not to necessitate any change in therapy.  Studies of greater length involving larger numbers of 442 
patients are required before any conclusions can be drawn about the safety profile of ATL1103.  443 
 444 
There were no clinically significant changes in pituitary tumour size, but the short duration of 445 
treatment precludes meaningful conclusions about the long-term impact of ATL1103 on this 446 
parameter.  Both the patients in whom tumour expansion of >2 mm was documented had discontinued 447 
somatostatin analogue therapy (one octreotide, one lanreotide) prior to commencing ATL1103, raising 448 
the possibility of rebound expansion from somatostatin analogue-induced tumour shrinkage. 449 
Reassuringly, the experience from more than 10 years’ use of pegvisomant is that GHR-targeted 450 
therapy does not induce growth of pituitary adenomas.20  451 
 452 
In summary, ATL1103 lowers IGF-I in acromegaly with biochemical changes consistent with down-453 
regulation of the GHR.  As IGF-I was still declining at the end of the treatment period and with the 454 
knowledge that the dose per kilogram could be increased, ATL1103 has the potential to achieve 455 
disease control in a significant proportion of patients.  Placebo-controlled studies of longer duration 456 
and using higher doses are needed to better assess the full potential of this novel treatment.   457 
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Tables 558 
Table 1: Baseline Characteristics of Patients With Acromegaly  559 
 200 mg ATL1103 once weekly 200 mg ATL1103 twice 
weekly 
 Median (range) Median (range) 
Number of patients 13 13  
Age – years 49 (26–72) 49 (32–80) 
Sex – M/F 5/8 6/7  
Duration of disease*–  years 9.0 (1–24) 3 (<1–20) 
Weight – kg 90.6 (73.4–113.9) 83.2 (58–131.6) 
Height – cm 169 (154–194) 163 (148–197) 
Body mass index – kg/m2 31.8 (26.0–39.6) 29·4 (21.4–45.3) 
     
Size of adenoma at diagnosis – no. 
(%) 
    
Micro (<10 mm) 2 (18%) 2 (16.7%) 
Macro (> or = 10 mm) 9 (81.8%) 10 (83.3%) 
Missing 2 1 
     
Hypopituitarism at study entry – no. 
(%) 
4 (30.8%) 4 (30.8%) 
     
Previous therapy – no. (%)     
Surgery 13 (100%) 12 (92.3%) 
Radiotherapy (all modalities) 6 (46.2%) 5 (38.5%) 
Dopamine agonist therapy 3 (23%) 5 (38.5%) 
Somatostatin analogue therapy 11 (84.6%) 12 (92.3%) 
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Pegvisomant therapy 7 (53.8%) 5 (38.5%) 
     
Serum growth hormone - ng/mL 3.6 (0.4–60.6) 3.5 (1.5–9.4) 
GH nadir (Screening OGTT) – ng/mL 2.5 (0.29–54.69) 2.4 (0.37–5.52) 
Serum IGF-I – ng/mL 447 (205–975) 642 (239–831)† 
Serum GHBP – pM 1179.0 (386–7637) 525.0 (<69–6434)‡ 
Serum IGFBP-3 – ng/mL 6589.0 (5162–9630) 7005.0 (3396–9843) 
ALS – mU/mL 1669.0 (1395–2829) 1970.0 (945–2463) 
 
    
Ring size circumference – mm 63.8 (57.5–81.4) 67.5 (53.7–78.9) 
AcroQoL – global score 58 (18–100) 71 (56–90) 
SSS – calculated maximum score 20.0 (1–36)§ 11 (7–30) 
GH, growth hormone; OGTT, IGF-I, insulin-like growth factor 1; GHBP,growth hormone binding 560 
protein; ALS, acid labile subunit; IGFBP-3 , insulin-like growth factor binding protein 3; SSS, signs 561 
and symptoms score. 562 
*Years from initial diagnosis to first day of study. 563 
†Baseline IGF-I missing for one patient, screening IGF-I value used for calculations. 564 
‡n=12, baseline GHBP missing for one patient. 565 
§n=12, baseline SSS missing for one patient. 566 
 567 
  568 
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 569 
Table 2. Summary of Treatment-emergent Adverse Events (Safety Set)* 
 200 mg once 
weekly (n=13) 
200 mg twice weekly 
(n=13) 
Total (N=26) 
 n N % n N % n N % 
TEAEs 98 11 84.6 88 11 84.6 186 22 84.6 
Drug-related TEAEs† 33 6 46.2 24 8 61.5 57 14 53.8 
Serious TEAEs 3 1 7.7 1 1 7.7 4 2 7.7 
Severe drug-related TEAEs 0 0  0 0  0 0  
Severe TEAEs 6 3 23.1 1 1 7.7 7 4 15.4 
TEAEs leading to permanent 
discontinuation of study drug 
0 0  0 0  0 0  
Withdrawals 1§   1§     
          
Patients with ISR 11  84.6 11  84.6 22   
Mild  9           6     15  
Moderate  2   5   7  
Severe  0   0   0  
 
 
Most frequent TEAEs with a 
>15% incidence 
 
         
Headache 21 4 30.8 5 3 23.1 26 7 26.9 
Fatigue 3 2 15.4 3 2 15.4 6 4 15.4 
Diarrhoea 3 2 15.4 2 2 15.4 5 4 15.4 
Constipation 2 2 15.4 2 2 15.4 4 4 15.4 
Dizziness 1 1 7.7 4 2 15.4 5 3 11.5 
Hyperhidrosis 1 1 7.7 4 2 15.4 5 3 11.5 
Rash 3 1 7.7 2 2 15.4 5 3 11.5 
Abdominal pain upper 1 1 7.7 2 2 15.4 3 3 11.5 
Nasopharyngitis 2 2 15.4 1 1 7.7 3 3 11.5 
Urinary tract infection 3 2 15.4 0 0  3 2 7.7 
Oropharyngeal pain 0 0  3 2 15.4 3 2 7.7 
Abdominal distension 0 0  2 2 15.4 2 2 7.7 
Abdominal pain 0 0  2 2 15.4 2 2 7.7 
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Tracheitis 2 2 15.4 0 0  2 2 7.7 
Carpal tunnel syndrome 2 2 15.4 0 0  2 2 7.7 
Haematuria 2 2 15.4 0 0  2 2 7.7 
Lipohypertrophy 2 2 15.4 0 0  2 2 7.7 
ISR, injection site reaction; N, number of patients; n, number of events; %, percentage of patients; TEAE, 
treatment-related adverse event. 
*Excludes ISRs. 
†Drug related is defined as relationship to study drug = possible, probable, or definite. 
§Withdrew consent after last drug dose.  
 
 570 
 571 
 572 
 573 
 574 
 575 
  576 
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Table 3. Summary of Abnormal Liver Function Tests. 577 
Analyte Week Result Reference range 
200 mg once weekly    
↑GGT, U/L 8 159 (repeats: 65, 32) 8–61 
 21 102  
↑AST, U/L 8 111 (repeats: 70, 26) 6–40 
↑ALT, U/L 8 181 (repeat: 135) 6–40 
↑ALP, U/L 8 200 40–128 
200 mg twice weekly    
↑AST, U/L 4 42 2–31 
 8 43  
↑ALT, U/L 4 69 8–34 
 8 99  
 13 52  
↑Total bilirubin (μmol/L) 1 28 0–21 
 2 22  
 4 26  
GGT, gamma-glutamyl transferase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; 578 
ALP, alkaline phosphatase. 579 
  580 
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Figures 581 
 582 
Figure 1. Cartoon representation of ATL1103 and the mechanism of antisense inhibition. 583 
ATL1103 is a second-generation, 20-mer antisense oligonucleotide with a phosphorothioate backbone 584 
and 2’-O-methoxyethyl modifications of the terminal five nucleotides at each end, which in 585 
combination increase its plasma half-life and affinity for the mRNA. Post-hybridization RNaseH 586 
degradation results in inhibition of GHR translation. 587 
 588 
 589 
GHR, growth hormone receptor. 590 
  591 
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Figure 2. Schematic representation of study protocol. 592 
The protocol entailed appropriate washout from any ongoing acromegaly medical therapy after which 593 
serum IGF-I had to be at least >1.3 times age-related ULN. All patients underwent pituitary MRI 594 
scans at baseline and completion of the study drug.  An OGTT was undertaken at baseline (after 595 
washout) and again at the end of week 13. 596 
 597 
IGF-I, insulin-like growth factor 1; ULN, upper limit of normal; MRI, magnetic resonance imaging; 598 
OGTT, oral glucose tolerance test.  599 
 600 
  601 
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Figure 3. Patient disposition. 602 
 603 
 604 
aFive patients failed screening as IGF-I was <130% ULN.  605 
bAlthough powered for 12 patients per arm, 13 were included per arm since a commitment had been 606 
made to allow patients consented and ‘passing’ screening to receive study drug.   607 
IGF-I, insulin-like growth factor 1; ULN, upper limit of normal. 608 
 609 
  610 
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Figure 4. Median percentage change from baseline in serum concentrations of IGF-I in patients 611 
with acromegaly.   612 
In the patients randomised to ATL1103 200 mg twice weekly, the median fall in serum IGF-I was 613 
27.8%  (p=0.0002a) at the end of the treatment phase (week 14, 1 week after the last dose of study drug) 614 
compared to baseline (week 0).  Between cohort analysis at week 14 demonstrated the median fall in 615 
serum IGF-I to be 25.8% (p=0.0012) with twice- compared to once-weekly dosing. In the twice-weekly 616 
cohort, IGF-I was still declining at week 14, and at week 21 remained lower than at baseline by a median 617 
of 18.7% (p=0.0005b).  618 
 619 
 620 
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 621 
medians and interquartile ranges plotted 622 
 623 
 624 
 625 
  626 
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Figure 5. Percentage change in serum IGF-I levels from baseline to week 14 in 26 patients 627 
treated with 200 mg  ATL 1103 once or twice weekly.  628 
 629 
 630 
IGF-I, insulin-like growth factor . 631 
  632 
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Figure 6. Scatterplot of the percentage change from baseline in IGF-I at week 14 by the 633 
allocated dose per kg per week.   634 
Combining the data from the two dosing regimens demonstrated a highly statistically significant 635 
(p=0.0001) correlation with an estimated slope of regression of –8.27 (95% CI –11.97 to –4.56). 636 
 637 
IGF-I, insulin-like growth factor 1; CI, confidence interval.  638 
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Figure 7. Trapezoidal AUC for GH during OGTTs at baseline and week 14.  639 
In the twice-weekly cohort, the median increase in AUC was 46% at week 14 compared to baseline 640 
(p=0.001).  There was no change in GH levels in the once-weekly cohort.    641 
 642 
 643 
 644 
AUC, area under the curve; GH, growth hormone; OGTT, oral glucose tolerance test; CI, confidence 645 
interval. 646 
  647 
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Figure 8. Median percentage change from baseline in serum concentrations of GHBP in patients 648 
with acromegaly.   649 
Twice-weekly ATL1103 resulted in a median decline of 48.8% in GHBP (p=0.005a) at week 14 (open 650 
symbols), while a median fall of 23.6% was seen in the once-weekly cohort (p=0.027a).  In the twice 651 
weekly cohort, at week 21 the median fall in GHBP, compared to baseline, was 40.4% (p=0.008b).  652 
 653 
medians and interquartile ranges plotted 654 
 655 
